Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Tuesday, December 18, 2018 · 471,463,492 Articles · 3+ Million Readers

BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. and BEIJING, China, Dec. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on November 30, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 46,689 American Depositary Shares to 144 new employees under BeiGene’s Amended and Restated 2018 Inducement Equity Plan.

/EIN News/ -- The Amended and Restated 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

The restricted share units will vest 25 percent on each anniversary of the grant, subject to the employees’ continued employment with BeiGene or one of its subsidiaries. The restricted share units are subject to the terms and conditions of BeiGene’s Amended and Restated 2018 Inducement Equity Plan and forms of award agreements covering the grants.

About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i

Investor Contact          Media Contact
Craig West      Liza Heapes
+1 857-302-5189  +1 857-302-5663
ir@beigene.com    media@beigene.com

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.


BEI_ONC_4C_FlatLogo_Horizontal.jpg

Powered by EIN News
Distribution channels: Technology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release